Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.
Irene Brana
No relevant relationships to disclose
Jhanelle Elaine Gray
No relevant relationships to disclose
Paul Haluska
Consultant or Advisory Role - Merck (U)
Research Funding - Merck
Raanan Berger
Consultant or Advisory Role - advisory board (U)
Talia Golan
Consultant or Advisory Role - advisory board (U)
Mary Elizabeth Jones
Employment or Leadership Position - Merck
Stock Ownership - Merck
Alexandra Gunchenko
Employment or Leadership Position - Merck
Stock Ownership - Merck
Jonathan D. Cheng
Employment or Leadership Position - Merck
Stock Ownership - Merck
Research Funding - Merck
Lillian L. Siu
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche/Genentech